Mongolia vs Sur: The number of people with susceptibility test result for rifampicin
Mongolia
100
in 2021
Sur
97.1
in 2021
Mongolia rank
2nd
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Mongolia
- Sur
How they compare
Mongolia currently reports 100 against 97.1 in Sur, a difference of 2.9.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Sur ahead.
Mongolia ranks 2nd and Sur ranks 2nd of 146 countries.
Across the 2 decades both report, Mongolia averaged higher in 1 and Sur in 1.
Head to head by decade
| Decade | Mongolia | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 74.64 | 86.78 | 12.14 | Sur |
| 2020s | 100 | 97.8 | 2.2 | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Mongolia or Sur?
- Mongolia, at 100 against 97.1 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Mongolia and Sur?
- 2.9, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do Mongolia and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- Mongolia ranks 2nd and Sur ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.